Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores

Task Force/Committee Members, Rating Panel

Research output: Contribution to journalArticle

Abstract

Background: Muir-Torre syndrome (MTS) is a rare inherited syndrome, with an increased risk of sebaceous and visceral malignancy. Prior reports suggest screening for mismatch repair (MMR) deficiency may be warranted in patients <50 years and when sebaceous neoplasms are located on a non-head and neck location. Previously, appropriate use criteria (AUC) were developed for clinical scenarios in patients >60 years concerning the use of MMR protein immunohistochemistry (MMRP-IHC). This analysis explores the appropriateness of testing in patients ≤60 years. Methods: Panel raters from the AUC Task Force rated the use of MMRP-IHC testing for MTS for previously rated scenarios with the only difference being age. Results: Results verify the previously developed AUC for the use of MMRP-IHC in neoplasms associated with MTS in patients >60 years. Results also show that in patients ≤60 years with a single sebaceous tumor on a non-head and neck site, MMRP-IHC testing should be considered. Testing can also be considered with a 2-antibody panel on periocular sebaceous carcinoma in younger patients. Conclusions: Our findings align with known evidence supporting the need to incorporate clinical parameters in identifying patients at risk for MTS, with age being a factor when considering MMRP-IHC testing.

Original languageEnglish (US)
JournalJournal of Cutaneous Pathology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Muir-Torre Syndrome
Immunohistochemistry
Proteins
Area Under Curve
Neoplasms
DNA Mismatch Repair
Advisory Committees
Neck
Carcinoma
Antibodies

Keywords

  • anatomic location
  • appropriate use criteria
  • expert rating
  • immunohistochemistry
  • mismatch repair protein analysis
  • Muir-Torre syndrome
  • patient age
  • sebaceous neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Dermatology

Cite this

Muir-Torre syndrome appropriate use criteria : Effect of patient age on appropriate use scores. / Task Force/Committee Members; Rating Panel.

In: Journal of Cutaneous Pathology, 01.01.2019.

Research output: Contribution to journalArticle

@article{2a92364435ba42c4a8845a2a78a250e7,
title = "Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores",
abstract = "Background: Muir-Torre syndrome (MTS) is a rare inherited syndrome, with an increased risk of sebaceous and visceral malignancy. Prior reports suggest screening for mismatch repair (MMR) deficiency may be warranted in patients <50 years and when sebaceous neoplasms are located on a non-head and neck location. Previously, appropriate use criteria (AUC) were developed for clinical scenarios in patients >60 years concerning the use of MMR protein immunohistochemistry (MMRP-IHC). This analysis explores the appropriateness of testing in patients ≤60 years. Methods: Panel raters from the AUC Task Force rated the use of MMRP-IHC testing for MTS for previously rated scenarios with the only difference being age. Results: Results verify the previously developed AUC for the use of MMRP-IHC in neoplasms associated with MTS in patients >60 years. Results also show that in patients ≤60 years with a single sebaceous tumor on a non-head and neck site, MMRP-IHC testing should be considered. Testing can also be considered with a 2-antibody panel on periocular sebaceous carcinoma in younger patients. Conclusions: Our findings align with known evidence supporting the need to incorporate clinical parameters in identifying patients at risk for MTS, with age being a factor when considering MMRP-IHC testing.",
keywords = "anatomic location, appropriate use criteria, expert rating, immunohistochemistry, mismatch repair protein analysis, Muir-Torre syndrome, patient age, sebaceous neoplasms",
author = "{Task Force/Committee Members} and {Rating Panel} and Vidal, {Claudia I.} and Angela Sutton and Armbrect, {Eric A.} and Lee, {Jason B.} and Litzner, {Brandon R.} and Hurley, {M. Yadira} and Murad Alam and Duncan, {Lyn M.} and Elston, {Dirk M.} and Emanuel, {Patrick O.} and Tammie Ferringer and Fung, {Maxwell A} and Hosler, {Gregory A.} and Lazar, {Alexander J.} and Lori Lowe and Plaza, {Jose A.} and Robinson, {June K.} and Andras Schaffer",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/cup.13459",
language = "English (US)",
journal = "Journal of Cutaneous Pathology",
issn = "0303-6987",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Muir-Torre syndrome appropriate use criteria

T2 - Effect of patient age on appropriate use scores

AU - Task Force/Committee Members

AU - Rating Panel

AU - Vidal, Claudia I.

AU - Sutton, Angela

AU - Armbrect, Eric A.

AU - Lee, Jason B.

AU - Litzner, Brandon R.

AU - Hurley, M. Yadira

AU - Alam, Murad

AU - Duncan, Lyn M.

AU - Elston, Dirk M.

AU - Emanuel, Patrick O.

AU - Ferringer, Tammie

AU - Fung, Maxwell A

AU - Hosler, Gregory A.

AU - Lazar, Alexander J.

AU - Lowe, Lori

AU - Plaza, Jose A.

AU - Robinson, June K.

AU - Schaffer, Andras

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Muir-Torre syndrome (MTS) is a rare inherited syndrome, with an increased risk of sebaceous and visceral malignancy. Prior reports suggest screening for mismatch repair (MMR) deficiency may be warranted in patients <50 years and when sebaceous neoplasms are located on a non-head and neck location. Previously, appropriate use criteria (AUC) were developed for clinical scenarios in patients >60 years concerning the use of MMR protein immunohistochemistry (MMRP-IHC). This analysis explores the appropriateness of testing in patients ≤60 years. Methods: Panel raters from the AUC Task Force rated the use of MMRP-IHC testing for MTS for previously rated scenarios with the only difference being age. Results: Results verify the previously developed AUC for the use of MMRP-IHC in neoplasms associated with MTS in patients >60 years. Results also show that in patients ≤60 years with a single sebaceous tumor on a non-head and neck site, MMRP-IHC testing should be considered. Testing can also be considered with a 2-antibody panel on periocular sebaceous carcinoma in younger patients. Conclusions: Our findings align with known evidence supporting the need to incorporate clinical parameters in identifying patients at risk for MTS, with age being a factor when considering MMRP-IHC testing.

AB - Background: Muir-Torre syndrome (MTS) is a rare inherited syndrome, with an increased risk of sebaceous and visceral malignancy. Prior reports suggest screening for mismatch repair (MMR) deficiency may be warranted in patients <50 years and when sebaceous neoplasms are located on a non-head and neck location. Previously, appropriate use criteria (AUC) were developed for clinical scenarios in patients >60 years concerning the use of MMR protein immunohistochemistry (MMRP-IHC). This analysis explores the appropriateness of testing in patients ≤60 years. Methods: Panel raters from the AUC Task Force rated the use of MMRP-IHC testing for MTS for previously rated scenarios with the only difference being age. Results: Results verify the previously developed AUC for the use of MMRP-IHC in neoplasms associated with MTS in patients >60 years. Results also show that in patients ≤60 years with a single sebaceous tumor on a non-head and neck site, MMRP-IHC testing should be considered. Testing can also be considered with a 2-antibody panel on periocular sebaceous carcinoma in younger patients. Conclusions: Our findings align with known evidence supporting the need to incorporate clinical parameters in identifying patients at risk for MTS, with age being a factor when considering MMRP-IHC testing.

KW - anatomic location

KW - appropriate use criteria

KW - expert rating

KW - immunohistochemistry

KW - mismatch repair protein analysis

KW - Muir-Torre syndrome

KW - patient age

KW - sebaceous neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85065020153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065020153&partnerID=8YFLogxK

U2 - 10.1111/cup.13459

DO - 10.1111/cup.13459

M3 - Article

AN - SCOPUS:85065020153

JO - Journal of Cutaneous Pathology

JF - Journal of Cutaneous Pathology

SN - 0303-6987

ER -